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The data on long-term application of non-invasive ventilation (NIV) in patients with chronic
respiratory failure due to COPD are contradictory. We evaluated the effect of the addition
of NIV to optimal treatment for 1 year on the quality of life of stable hypercapnic COPD
patients.
NIV was offered to 49 of 58 initially enrolled consecutive patients, of whom 22 refused NIV
and comprised the standard treatment group whereas 27 received NIV. Quality of life was
assessed with the SF-36 questionnaire. Additional measurements included blood gases,
pulmonary function tests, dyspnea, daytime sleepiness, exacerbations and hospitaliza-
tions.
The NIV group showed a significant improvement in quality of life in the third month, both
in the Physical (3174 to 3878, po0.0001) and the Mental Component Summary Score
(2877 to 40710, p ¼ 0.009), that was maintained until the twelfth month. PaCO2
decreased by the first month in the NIV group (5474.5 to 44.675.6mmHg, po0.0001),
and PaO2 rose during the sixth month (58.975.7 to 64.476.5mmHg, p ¼ 0.004). Dyspnea
and diurnal sleepiness improved significantly. No significant improvements were observed
in the control group. Patients on NIV spent less days in the hospital compared to controls.
NIV when added to optimal medical treatment has beneficial effects on quality of life inElsevier Ltd. All rights reserved.
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One-year NIV in COPD: Effect on quality of life 905stable hypercapnic COPD patients, with additional improvements in arterial blood gases,
dyspnea and daytime sleepiness.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Non-invasive ventilation (NIV) has been shown to be an
effective treatment for acute hypercapnic respiratory fail-
ure in chronic obstructive pulmonary disease (COPD).1,2 In
contrast, the data on long-term application of NIV in
patients with chronic respiratory failure due to COPD are
still contradictory. Early controlled trials have reported
conflicting results,3,4 whereas subsequent studies presenting
positive outcomes of NIV were uncontrolled.5,6
A Cochrane meta-analysis concluded that nocturnal NIV
for at least 3 months in hypercapnic patients with stable
COPD had no consistent clinically or statistically significant
effect on lung function, gas exchange, respiratory muscle
strength, sleep efficiency or exercise tolerance, but the
small sample sizes precluded definite conclusions regarding
the effects of chronic application of NIV in patients with
COPD.7 In contrast, a recent systematic review concluded
that, in a subset of COPD patients, NIV may have an
adjunctive role in the management of chronic respiratory
failure.8 This review has shown inconsistencies in physiologic
outcomes, but more consistent improvements in health-
related quality of life (HRQoL) and dyspnea; however, those
health-related outcomes were the least studied outcomes in
the existing literature.8 In patients with severe disability
due to chronic disease though, quality of life may be more
important than prolongation of life or improvement in
physiologic outcomes.9
The aim of the present study was to evaluate the effect of
the addition of nocturnal NIV to optimal standard treatment
compared to standard treatment alone on HRQoL in a cohort
of patients with severe COPD with chronic hypercapnic
respiratory failure on stable condition. Additionally, we
evaluated the effect on dyspnea, gas exchange, pulmonary
function, daytime sleepiness and morbidity, as expressed
with acute exacerbations and hospital admissions.Methods
Patient selection
Fifty-eight patients with chronic hypercapnic respiratory
failure due to severe and very severe COPD, as defined by
the ATS/ERS guidelines,10 were consecutively enrolled in the
trial from September 2005 until December 2006. Home NIV
was offered to all eligible patients and all patients who
agreed to receive it constituted the NIV group, whereas all
patients who declined constituted the standard treatment
group. The study protocol was approved by the ethics
committee of our hospital and written informed consent was
obtained from all study participants.
Patients were included in the study if they met the
following criteria: agep75 years, smoking history420 pack
years, post-bronchodilator forced expiratory volume in 1 s(FEV1)o50% predicted and FEV1/forced vital capacity (FVC)
o70% on stable condition. Chronic hypercapnic respiratory
(CRF) failure was defined according to arterial blood gases
values, i.e. PaO2o60mmHg, PaCO2450mmHg on room air
on stable condition, prior to the inclusion in the study.
During enrolment, all patients were in stable clinical state,
as assessed by a pH47.35, and were free from exacerba-
tions at least 4 weeks preceding recruitment. Patients were
excluded if they presented significant co-morbidities (ob-
structive sleep apnea syndrome and obesity hypoventilation
syndrome, respiratory failure resulting from other causes
than COPD (i.e. post-TB, kyphoskoliosis), or important
concomitant chronic systemic disorders (chronic heart fail-
ure, chronic renal insufficiency, or malignancy)). To rule out
the coexistence of obstructive sleep apnea and obesity-
hypoventilation syndrome, all patients were initially
screened with nocturnal polysomnography. Sleep studies
were staged according to the criteria of Rechtschaffen and
Kales.11 Patients were excluded if they presented an
apnea–hypopnea index X10 episodes/h. Patients who pre-
sented poor compliance to the use of the ventilator (i.e.
mean use o5 h/day) at the first follow-up visit were also
excluded from subsequent follow-up.
Standard treatment
All patients were receiving optimal treatment according to
current guidelines, including long-acting bronchodilators,
inhaled corticosteroids, theophylline and long-term oxygen
therapy (LTOT), as indicated.10 No patient was attending a
rehabilitation program. During exacerbations, antibiotics
and systemic corticosteroids were prescribed, based on
clinical judgment. The decision for hospitalization during
exacerbations was taken by the attending physician, based
on clinical criteria and the severity of exacerbations.10
Ventilatory support
Patients were hospitalized for 2–3 days during the initial
application of NIV, in order to ensure maximal compliance.
NIV was administered in the spontaneous/timed mode via a
full face mask using a bi-level positive airway pressure
system (VPAP III ST, ResMed, Sydney, Australia). This mode
was chosen for the ability to set inspiratory and expiratory
times and it has been proved effective in COPD patients.5
Inspiratory and expiratory positive airway pressures (in-
spiratory positive airway pressure (IPAP) and expiratory
positive airway pressure (EPAP), respectively) were adjusted
according to the patient’s comfort and synchrony with the
ventilator and a marked reduction in the use of accessory
muscles. For the first 2 h from the initiation of ventilation,
the patient was observed by a pulmonologist and a fully
trained nurse, in order to assure a decrease in accessory
respiratory muscle use and respiratory rate, check the
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of the system. Supplemental oxygen was added in order to
maintain saturation between 88% and 92%. Arterial blood
gases were measured 1 h after the initiation of ventilation. A
decrease in PaCO2 values 45% was considered as adequate
ventilatory support.12 Subsequently, the patients were
trained in-hospital until they were fully confident in using
the ventilator. Technically skilled personnel installed the
ventilator at the patients’ home and provided full technical
support when required.
Measurements
Spirometry was performed with a dry spirometer (KoKo
Legend, Ferraris, UK), according to the ATS guidelines.13
Arterial blood gases were measured at rest, with the patient
in sitting position, while breathing room air or with
supplemental oxygen aiming to keep pulse oximetric
saturation (SpO2) at approximately 88–92%. Dyspnea was
assessed with the Medical Research Council (MRC) dyspnea
scale.14 Subjective daytime sleepiness was evaluated with
the Epworth Sleepiness Scale (ESS),15 that has been
validated for the Greek language.16
The evaluation of HRQoL was made using the validated
Greek version of the SF-36 Health Survey (Version 2).17 This
instrument has been proven valid to measure HRQoL in
patients with COPD,18 and has successfully been used in
evaluating HRQoL in patients with different causes of
chronic respiratory failure (CRF) receiving domiciliary non-
invasive mechanical ventilation.5,19–21 The SF-36 consists of
36 items on eight subscales measuring different aspects of
general health: Physical Functioning, Role Physical, Role
Emotional, Bodily Pain, General Health, Vitality, Social
Functioning, Mental Health. In each subscale a standardized
score between 0 and 100 is produced, with lower scores
indicating poorer health or higher disability. The scales can
be aggregated to two summary measures (PCS, Physical
Component Summary and MCS, Mental Component Sum-
mary).
Study protocol
Study participants were evaluated in the NIV outpatient
clinic on the first, third, sixth, ninth and twelfth month after
the initial evaluation. If the patient had an exacerbation,
the measurements were obtained 1 month after the event.
In every appointment, physical examination, arterial blood
gases, spirometry, MRC dyspnea, HRQoL and ESS were
assessed. In the control group, the hours of LTOT were
reported by the individual patients, whereas in the subjects
in the NIV group, the settings and the hours of usage of the
ventilator (obtained from the time counter) were evalu-
ated, in order to determine proper usage and compliance.
During the follow-up period, patients underwent adjust-
ments in NIV masks or ventilator settings as needed in order
to maintain patient–ventilator synchrony and optimize gas
exchange and functional status. Additional measurements
recorded included the number of exacerbations, hospital
admissions, number of in-hospital days, the need for
intubation and number of deaths during the follow-up
period of 1 year.Statistics
Data are presented as mean7standard deviation (S.D.),
with ranges in parentheses, unless otherwise mentioned.
Comparisons between two groups were performed with
independent samples t-tests, whereas comparisons among
three or more groups were performed with one-way analysis
of variance (ANOVA) using an appropriate post-hoc test
(Bonferroni).
In order to define determinants of HRQoL at the end of
the trial, stepwise multiple linear regression models were
created, using Physical and Mental Component Summaries as
dependent variables, and PaO2, PaCO2, HCO3
, FEV1, FVC,
FEV1/FVC, MRC, ESS at the end of the trial, number of
exacerbations and number of in-hospital days spent per year
as independent variables. Stepwise multiple linear regres-
sion models were also used to identify determinants of the
change in HRQoL in the NIV group using as independent
variables the changes in PaO2, PaCO2, HCO3, MRC, ESS
(DPaO2, DPaCO2, DHCO3, DMRC, DESS) and the number of
exacerbations and number of in-hospital days spent per
year. A similar model was used to identify determinants of
the change in the degree of dyspnea, using IPAP, EPAP and
hours of ventilator use as independent variables. A p-value
o0.05 was considered statistically significant. Data were
analyzed with SPSS 12.0 and Sigma Plot 8 software.Results
Patient characteristics
From the initial 58 COPD patients that were evaluated, nine
were excluded from the study (six had AHI 410 events/h
and three had obesity-hypoventilation syndrome with a BMI
435 kg/m2). NIV was offered to all of the remaining 49
patients. However, 22, although they presented a good
compliance with the ventilator during the hospital stay,
refused to continue NIV on a long-term basis at home. These
patients constituted the control group and the remaining 27
patients received NIV. In the NIV group, there were three
early dropouts due to poor compliance with the ventilator
(o5 h/day), leaving 24 patients for follow-up for the whole
study period in that group.
Patients’ baseline characteristics are shown in Table 1.
There were no statistically significant differences between
groups according to their age, spirometric values, arterial
blood gases, dyspnea, daytime sleepiness or HRQoL. Patients
that received NIV presented a trend for higher BMI com-
pared to controls that did not however reach statistical
significance.Ventilator settings and compliance
Patients in the NIV group received ventilation for 972.2 h/
24 h. The mean ventilator settings after the establishment
of NIV were as follows: IPAP 15.372.0 cmH2O (range 12–
18 cmH2O) and EPAP 5.470.7 cmH2O (range 4–8 cmH2O). All
patients were receiving supplemental oxygen at home
(range 1–3 L/min). All patients in the control group received
LTOT (range 1–3 L/min) for 17.172.3 h/24 h.
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Table 1 Patient characteristics.
Control group (n ¼ 22) NIV group (n ¼ 24) p-Value
Age (years) 68.975.6 65.278.9 0.101
Gender (F/M) 8/14 7/17
BMI (kg/m2) 27.873.4 30.475.7 0.073
AHI (events/h) 5.773.1 4.273.7 0.158
FEV1 (% predicted) 35.1710.3 34.7711.3 0.730
FVC (% predicted) 47.4713.1 50.8715.7 0.325
PaO2 (mmHg) 58.474.8 58.975.7 0.746
PaCO2 (mmHg) 55.474.6 54.174.4 0.343
pH 7.41270.038 7.41070.029 0.897
HCO3
 (mmol/L) 35.973.4 35.373.7 0.561
Dyspnea (MRC scale) 4.270.4 3.970.5 0.073
ESS score 9.273.7 10.275.7 0.478
SF-36 PCS 29.474.1 31.574.4 0.111
SF-36 MCS 32.379.6 28.376.8 0.112
Data are presented as mean7S.D. M, male; F, female; BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital
capacity; MRC, Medical Research Council; ESS, Epworth sleepiness scale; SF-36, short form 36 questionnaire; PCS, physical component
summary; MCS, mental component summary.
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Figure 1 Time course of arterial carbon dioxide tension
(PaCO2) during the study period in the control and NIV groups.
Each time point represents the mean value with S.D. Significant
differences from baseline at each time point in either group are
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Spirometric parameters did not change significantly through-
out the study period. A significant reduction in PaCO2 was
observed in the first month in the NIV group (54.174.5 to
44.675.6mmHg, po0.0001), which was maintained until the
twelfth month. A corresponding reduction of HCO3
 was
observed (35.373.7 to 29.273mmol/L, po0.0001). More-
over, there was a significant increase in PaO2 during the sixth
month in the NIV group (58.975.7 to 64.476.5mmHg,
p ¼ 0.004), which was maintained thereafter. In contrast,
there were no changes in arterial blood gases in the control
group, except for a reduction in PaO2 during the third month
of the trial (58.474.8 to 55.175.1mmHg, p ¼ 0.032).
The time course of PaCO2 in the two groups is shown in
Figure 1.
Dyspnea (3.970.5 to 3.570.7, p ¼ 0.029) and daytime
sleepiness (10.275.7 to 4.872.2, po0.0001) improved
significantly in the NIV group by the first month. On the
other hand, the control group did not show any change
during follow up. The changes in dyspnea and ESS are
demonstrated in Figures 2 and 3.indicated as *po0.05, **po0.01, ***po0.001. Significant
differences between groups at each time point are indicated
as fpo0.001.Health-related quality of life
The NIV group showed a significant improvement in HRQoL in
the third month, both in the PCS score (3174 to 3878,
po0.0001) and in the MCS score (2877 to 40710,
p ¼ 0.009), that was maintained until the twelfth month.
This improvement was evident in most domains of the SF-36
questionnaire, except for the domain of Bodily Pain. The
control group did not present any significant improvements
in SF-36 domains, whereas there was a significant deteriora-
tion in Role Emotional (27714 to 16717, p ¼ 0.024) on the
sixth month that persisted until the end of the study.
Changes in PCS and MCS scores are presented in Figure 4A
and B. The changes in all eight domains of the SF-36questionnaire during the follow-up period are presented in
the online Supplement.Morbidity and mortality
Patients in the NIV group spent less days in the hospital
compared to controls (6.6714.1 vs. 16.0712.9 no./pa-
tient/year, respectively; p ¼ 0.023). However, there was
only a trend towards a lower number of exacerbations
(1.472.1 vs. 1.871.4 no./patient/year, respectively; p ¼
0.419) and exacerbations which led to hospitalization
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Figure 2 Time course of Medical Research Council dyspnea
score during the study period in the control and NIV groups.
Each time point represents the mean value with S.D. Significant
differences from baseline at each time point in either group are
indicated as *po0.05, **po0.01, ***po0.001. Significant
differences between groups at each time point are indicated
as ]po0.05, fpo0.001.
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Figure 3 Time course of Epworth Sleepiness Scale during the
study period in the control and NIV groups. Each time point
represents the mean value with S.D. Significant differences
from baseline at each time point in either group are indicated
as *po0.05, **po0.01, ***po0.001. Significant differences
between groups at each time point are indicated as ]po0.05,
fpo0.001.
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Figure 4 (A) Time course of Physical Component Summary
during the study period in the control and NIV groups. Each time
point represents the mean value with S.D. Significant differ-
ences from baseline at each time point in either group are
indicated as *po0.05, **po0.01, ***po0.001. Significant
differences between groups at each time point are indicated
as fpo0.001. (B) Time course of Mental Component Summary
during the study period in the control and NIV groups. Each time
point represents the mean value with S.D. Significant differ-
ences from baseline at each time point in either group are
indicated as *po0.05, **po0.01, ***po0.001. Significant
differences between groups at each time point are indicated
as ]po0.05, fpo0.001.
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in the NIV group compared to the control group, without
statistical significance.
Three patients required endotracheal intubation (one
from the NIV group and the other two from the control
group). Two patients died in the NIV group (8.33%), the first
one during the second month from myocardial infarction and
the second one during the third month due to COPD
exacerbation. Moreover, there were two deaths in the
control group (9.09%), both from COPD exacerbations.Determinants of HRQoL
Stepwise multiple linear regression analysis revealed that
MRC (po0.0001), FEV1/FVC (p ¼ 0.013) and PaO2 (p ¼
0.016) were independent predictors of PCS (R2 ¼ 0.844),
MRC being the major predictor of Physical Component
(R2 ¼ 0.780, po0.0001) in the whole study population at
the end of the trial. Additionally, MRC (po0.0001) and ESS
(po0.0001) were independent predictors of MCS were
(R2 ¼ 0.859), again with MRC being the major predictor of
Mental Component (R2 ¼ 0.768, po0.0001).
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HRQoL at the end of the trial was the change in the degree
of dyspnea (DMRC; for DPCS, R2 ¼ 0.513, po0.0001 and for
DMCS, R2 ¼ 0.367, p ¼ 0.005). Linear regression analysis
also revealed that the number of hours of ventilator use
were the only independent predictors of the change in MRC
at the end of the trial (R2 ¼ 0.230, p ¼ 0.004).Discussion
In the present prospective, controlled study of 1-year
duration we have shown that the addition of NIV to standard
medical treatment in selected patients with chronic
respiratory failure due to severe stable COPD improved
HRQoL. NIV additionally improved arterial blood gases,
dyspnea and daytime sleepiness, and reduced the number
of days spent in hospital, however with no effect on the
number of exacerbations. The improvement in the degree of
dyspnea was the major determinant of the change seen in
HRQoL, whereas the total number of hours spent on the
ventilator per day was an independent predictor of the
improvement in dyspnea. The present study is one of the
few studies evaluating HRQoL as a primary outcome in a
longitudinal evaluation of patients with chronic hypercapnic
respiratory failure due to severe COPD receiving NIV8 and
the first to our knowledge to prospectively evaluate
determinants of HRQoL in those patients.
COPD is a multi-system disorder and expiratory airflow
limitation can not express its effects (breathlessness,
fatigue, muscle wasting) comprehensively, a multi-dimen-
sional approach that is better evaluated with health status
measurements.22 In the present study, we have shown
prospectively that patients’ HRQoL improved along with
the improvement in respiratory failure in the NIV group.
Interestingly, this improvement was seen both in the
physical and the mental components of SF-36, starting from
the third month and persisting until the end of the 1-year
follow up. In a previous study, NIV added to LTOT improved
quality of life (SGRQ) compared to LTOT alone, but a clear
improvement from baseline HRQoL was seen only in the
symptoms score.23 Other cross-sectional studies have
evaluated the HRQoL of patients already receiving NIV at a
single time-point,19,21 and Euteneuer et al.19 showed that
quality of life is influenced by the severity of respiratory
failure. A recent systematic review highlights the scarce,
yet consistent, evidence of improvement in HRQoL with NIV
in severe stable COPD, stressing the need for further studies
in that direction.8 Our study provides prospective data
further supporting the positive impact of NIV in the HRQoL of
selected patients with chronic hypercapnic respiratory
failure due to severe COPD.
The type of the questionnaire used in clinical studies is of
great importance. In the Italian Multi-centre Study, the
authors showed that SGRQ total score did not change
significantly over the study period, whereas the MRF-28
was able to discriminate changes in quality of life in the
same study group.12 In the present study, we have used the
SF-36 questionnaire, which has been shown to be a valid
instrument to measure HRQoL in patients with COPD,18 and
has been successfully used in evaluating HRQoL in patients
with different causes of chronic respiratory failure receivingdomiciliary non-invasive mechanical ventilation.5,19–21
Moreover, with a generic questionnaire, more global issues
related to HRQoL can be assessed, such as social role,
mental health and general well being.24
A clear improvement in daytime arterial blood gases in
the NIV group was additionally demonstrated in our study.
Only one23 of the four randomized controlled trials3,23,25,26
included in the Cochrane meta-analysis27 demonstrated
similar favorable results. The degree of hypercapnic
respiratory failure before the application of NIV is also of
great importance. In the study by Casanova et al,25 some
patients were normocapnic (mean PaCO2, 50.777.9mmHg),
whereas trials with positive outcomes included more
hypercapnic patients.12,23,28 However, there is indirect
evidence that domiciliary NIV is unlikely to be effective in
normocapnic COPD patients.29 The other two trials3,26 had
shorter duration and included only a small number of
patients compared to our study. Trials where the daily
duration of ventilatory support was too short failed to show
any significant benefits in improving physiologic outcomes,4
whereas blood gases improved when the ventilator was
being used 46 h/day.12,23 We believe that a significant
reason for the positive outcomes in our study is the better
compliance of our patients and the higher total number of
hours spent on the ventilator compared to previous studies.
The levels of IPAP used in our trial were higher than the
ones used in most negative trials,3,4,25 and comparable to
the ones used by Clini et al.12 Only a single study has applied
higher levels of inspiratory pressures compared to ours
(mean IPAP 28 cmH2O) demonstrating favorable results in
improving blood gases and lung function.5 We believe that
ventilator settings are crucial for the achievement of
positive physiologic outcomes in COPD patients, since low
levels of pressure support (o10 cmH2O) deliver minute
ventilation that is similar to spontaneous ventilation, while
increased pressure supports (420 cmH2O) are associated
with increasing mask leaks.30 Additionally, the EPAP applied
in our trial was higher compared to the values used in all
other trials. Intrinsic positive end-expiratory pressure
(PEEPi) provides an inspiratory load which accounts for
about 40% of the total ventilatory workload.31 The applica-
tion of PEEP levels close to PEEPi (80–90% of PEEPi) can
substantially reduce inspiratory work of breathing, without
promoting further dynamic pulmonary hyperinflation,32–34
and we believe that this was the case in our study.
The degree of dyspnea significantly improved in the NIV
group, and dyspnea was the strongest determinant of both
PCS and MCS scores of the SF-36 at the end of the 1-year
follow-up. Dyspnea indices have been shown to influence
and predict general health status to a greater extent than
physiologic measurements in symptomatic patients with
COPD.35 Interestingly, the most significant determinant of
improvement in dyspnea in our NIV patients was the time
spent on the ventilator, suggesting that, besides ventilator
settings, patients’ compliance to NIV is important. Addi-
tionally, daytime sleepiness (as expressed by ESS) was a
significant predictor of the Mental Component of SF-36 and
decreased significantly with NIV. To our knowledge, this is
the first study in literature that provides data on daytime
sleepiness using the ESS in a COPD population. However,
daytime sleepiness is the most common reason to commence
home mechanical ventilation in hypercapnic NMD patients,36
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obesity-hypoventilation syndrome receiving NIV.37 Based on
our data, we suggest that the MRC dyspnea scale along with
the ESS may be useful for the long-term follow-up of COPD
patients on NIV; further studies are needed in that direction.
The number of exacerbations did not differ between
groups in the present study, despite a trend towards fewer
exacerbations in the NIV group. However, patients on NIV
spent significantly less days in hospital in the year of follow-
up compared to the control group, indicating that the latter
group may have experienced more severe exacerbations
requiring prolonged hospitalization. A plausible explanation
for that observation might be the improvement in the level
of hypercapnia in the NIV group. Although it has been shown
that patients with frequent exacerbations have worse
HRQoL,38 it seems that the severity of acute exacerbation,
as translated by the reduced number of in-hospital days,
may also be important. Finally, the two groups did not
present differences in mortality rates, but this was not a
major outcome in our study as the 1-year duration of the
trial was too short to evaluate mortality.
A major limitation of our study is that this is not a
randomized controlled trial. Non-invasive ventilation was
offered to all COPD patients and those who refused it
comprised the control group. However, the two groups were
well matched in terms of age, disease severity as expressed
by spirometry, arterial blood gases, dyspnea, daytime
sleepiness or HRQoL. Additionally, all patients were followed
up in an identical pattern and were closely supervised for
adherence to medical treatment. Finally, the patients in the
control group, although they refused NIV, this did not
suggest inherent incompliance, as they presented excellent
compliance to their treatment and presented in all the
scheduled appointments. Interestingly, these patients did
not present improvements in the evaluated physiological
outcomes or their HRQoL, despite the fact that they
received the best available supportive care and they were
closely followed up throughout the study. On the other
hand, the patients who agreed to receive NIV may have been
motivated, and this may account for the good compliance
with the use of the ventilator in this group.
In conclusion, the present study has shown that the
addition of NIV to optimal standard therapy has beneficial
effects in the HRQoL of stable hypercapnic COPD patients,
with the improvement in dyspnea being the major determi-
nant of HRQoL changes. Additional improvements in arterial
blood gases, dyspnea and daytime sleepiness, along with a
reduction in the total number of days spent in hospital for
acute exacerbations have been shown in the NIV group. The
higher inspiratory and expiratory pressures and the higher
time spent on NIV in the present study compared to previous
ones may account for the aforementioned positive outcomes.
Given the impact of severe COPD on patients and health
systems, larger studies focusing on patient-centered out-
comes, such as HRQoL, are urgently needed especially in the
era of wider availability and lower cost of NIV ventilators.Conflict of interest statement
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